Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Stichting Wageningen Research currently has a focused presence in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This single active matter is being handled within 1 distinct art unit, reflecting a specific technical focus for the current prosecution cycle. Because of this limited volume, the entire active portfolio is concentrated under the review of a distinct examiner. This focus suggests that the applicant's current interactions with the patent office are highly targeted rather than broad-based.
DELEO, VICTORIA LYNN is the busiest examiner for this portfolio, responsible for the pending office action currently on record. The ratio between the busiest examiner's workload and the total actions means that the outcome of the company's current prosecution efforts depends entirely on this interaction. With the distinct art unit involved, the applicant faces a streamlined but centralized examination environment. There is no distribution of risk across multiple examiners or departments at this time.
For a practitioner, this concentration means that understanding the specific tendencies and past decisions of DELEO, VICTORIA LYNN is paramount. The success of the Biotechnology & Pharmaceuticals filings for Stichting Wageningen Research is tied to the resolution of the active matter, making it the primary focus of their legal strategy. This lack of diversification in the current portfolio requires a high-stakes approach to the pending case. The applicant can dedicate full attention to the technical and procedural requirements of the assigned art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DELEO, VICTORIA LYNN | 1 | 41.4% | -44.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268409 | PROMOTING REGENERATION AND TRANSFORMATION IN BETA VULGARIS | DELEO, VICTORIA LYNN | 76d |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18268409 | PROMOTING REGENERATION AND TRANSFORMATION IN BETA VULGARIS | DELEO, VICTORIA LYNN | 1662 | §102§112 | Final Rejection | 76d | Pending | Jun 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStichting Wageningen Research has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Victoria Lynn Deleo has the most, with 1 of Stichting Wageningen Research's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
